New Huntington's drug shows promise in early safety trial
Disease control
Ongoing
This early-stage study tests an experimental drug, ER2001, in 27 adults with early Huntington's disease. The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo once a week for 6 weeks, with follow-up for 6 mo…
Phase: PHASE1, PHASE2 • Sponsor: ExoRNA Bioscience • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC